Fractyl Health (GUTS) vs TELA Bio (TELA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TELA Bio (TELA) has outperformed Fractyl Health (GUTS) over the past year, losing 31.4% versus a loss of 74.8%. Fractyl Health is the larger company by market cap ($56.1 million vs $47.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GUTS | TELA |
|---|---|---|
| Share price | $4.23 | $1.05 |
| Market cap | $56.11M | $47.40M |
| 1-day change | -6.42% | -1.87% |
| YTD return | -83.98% | -11.02% |
| 1-year return | -74.82% | -31.37% |
| 5-year return | — | -91.67% |
| EPS (TTM) | $-10.56 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.34 | $1.56 |
| 52-week low | $4.14 | $0.501 |
| Distance from 52-week high | -85.58% | -32.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1327.90% | +98.10% |
| Average volume | 152.04K | 214.83K |
| Shares outstanding | 13.26M | 45.14M |
| Employees | 100 | 218 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TELA has outperformed GUTS by 43.4 percentage points over the past year.
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Healthcare · Biotechnology · 100 employees
About TELA Bio
TELA stock →TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Healthcare · Medical Devices · 218 employees
GUTS vs TELA FAQ
Which is bigger, Fractyl Health or TELA Bio?
Fractyl Health (GUTS) is larger, with a market capitalization of $56.11M compared with $47.40M for TELA Bio (TELA).
Which stock has performed better over the past year, GUTS or TELA?
TELA returned -31.37% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Fractyl Health and TELA Bio in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Fractyl Health and Medical Devices for TELA Bio.